Ponatinib is the first FDA-approved third-generation BCR-ABL inhibitor for CML (Figure 1), which displayed excellent potency to inhibit BCR-ABLWT, BCR-ABLT315I, and other clinically significant ABL mutants, like Q252H, Y253H, M351T, and H396P15,.16 The gene discussed is ABL1; the disease is chronic myelogenous leukemia, BCR-ABL1 positive.